Stock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase

Stock Track

Mar 26

Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.

The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.

Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1100707834"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100707834\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100707834?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100707834","market":"hk","top_or_hot":-1,"title":"Stock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase","media":"Stock Track","content":"<p>Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.</p><p>The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.</p><p>Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-26 09:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.</p><p>The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.</p><p>Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09996","symbol_name":"沛嘉医疗-B","start_time":0,"source_url":"","article_id":"1100707834","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100707834","pubTimestamp":1774490141,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09996":"沛嘉医疗-B"},"translate_title":"个股赛道|沛嘉医疗盘中大涨5.28%，得益于强劲的2025财年业绩、监管批准、CEO购股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09996":1},"content_text":"Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}